Ceritinib, marketed under the brand name Zykadia, is a type of targeted cancer therapy that is used for the treatment of ALK (anaplastic lymphoma kinase)-positive advanced non-small cell lung cancer in adults. This highly effective targeted cancer therapy works by binding to ALK proteins, blocking their activity from producing cancer cells. This type of targeted cancer therapy is used as a first-line treatment in non-small cell lung cancer patients that have a known ALK fusion gene.
Results from clinical trials
Ceritinib has been shown to be highly effective in treating patients with advanced non-small cell lung cancer. In a study conducted by the Memorial Sloan Kettering Cancer Center in New York, ceritinib was found to be effective in achieving an overall response rate of 65.5%. This rate is significantly higher than the response rate of 15.2% in patients who were treated with chemotherapy. Additionally, the median progression-free survival rate in the ceritinib group was significantly longer at 11.7 months when compared to 6.3 months in the chemotherapy group. There were also notable differences in the overall survival rate, with the ceritinib group having an overall survival rate of 16.6 months in comparison to the chemotherapy group’s 10.4 months, indicating that ceritinib is more effective in prolonging the lives of patients with advanced non-small cell lung cancer than chemotherapy.
The effective value of second-line treatment
Ceritinib 150mg capsule uses as a second-line treatment in patients who have already received chemotherapy. The overall response rate for ceritinib in this setting is 45.9 %, which is again significantly better than the response rate seen with chemotherapy in this population (21.7%). In addition, the median progression-free survival time was longer in the ceritinib-treated patients at 6.7 months in comparison to 4 months in the chemotherapy-treated group. This indicates that ceritinib is an effective second-line treatment.
Chemotherapeutic mode of action
Ceritinib is a novel and innovative chemotherapeutic drug that demonstrates superior effectiveness compared to its predecessors. Recently developed by Novartis, ceritinib is a potent inhibitor of anaplastic lymphoma kinase (ALK) that is used in the treatment of metastatic non-small cell lung cancer (NSCLC). The drug is a member of the drug class known as kinase inhibitors and is taken orally. Ceritinib is believed to be more effective than crizotinib, an earlier kinase inhibitor, making it a valuable therapeutic tool in the treatment of ALK-positive NSCLC.
Cellular signaling involved in this process
Ceritinib functions by targeting ALK to inhibit its activity. ALK is a tyrosine kinase receptor that can amplify the cell proliferation pathways of malignant cells and alter the cell cycle, making it essential to the growth of most cancer cells. Ceritinib binds to the ALK receptor, blocking the tyrosine kinase activity and causing cancer cells to undergo apoptosis, resulting in the death of the malignant cells. In NSCLC cells that lack ALK mutations, ceritinib does not bind to the receptor and has no effect.
Widely accepted mode of clinical trials
Clinical trials have demonstrated that ceritinib is well tolerated and is more effective than crizotinib in the treatment of lung cancer. The drug has been approved for use in the United States, Europe, and Japan. In addition to treating metastatic NSCLC, it is also approved for the treatment of a rare form of the disease known as ROS1-positive advanced NSCLC. In a small study of 39 patients with NSCLC and ROS1 rearrangements, ceritinib was found to have a response rate of 72 percent in all patients, and a response rate of 94 percent in those who hadn’t previously received other forms of treatment.
Targetted mode of ceritinib action
Overall, the chemotherapeutic action of ceritinib is a major advance in the treatment of ALK-positive NSLC and ROS1-positive advanced NSCLC. Clinical trials have demonstrated its great efficacy, with a higher response rate than crizotinib. Ceritinib’s targeted action also limits its impact on malignant cells and reduces potential side effects, making it safer and more effective than previously available chemotherapeutics. As a result, ceritinib is a powerful addition to the arsenal of cancer drugs and provides a critical therapeutic tool for patients with NSCLC and ROS1-positive advanced NSCLC.
Ceritinib side effects
While ceritinib is a highly effective targeted cancer therapy, it is not without adverse effects. Common side effects include nausea, vomiting, fatigue, constipation, and diarrhea. In addition, there have been several reports of serious side effects associated with ceritinib, including liver failure and interstitial lung disease. However, these serious side effects are rare and the majority of patients will experience minimal to no adverse effects when taking ceritinib.
In short, ceritinib is highly effective in treating patients with ALK-positive advanced non-small cell lung cancer. The overall response rate is much higher than that of chemotherapy, and the median progression-free survival time is longer with ceritinib as well. There can be serious side effects associated with ceritinib, but they are rare and the majority of patients experience minimal to no adverse effects. Therefore, ceritinib is a highly effective targeted cancer
Also, read about- Lung Cancer